ALG-097558, Publications Discovery of ALG-097558, a Novel 3CL Protease Inhibitor with Activity in the SARS-CoV-2 Hamster Infection Model
ALG-097558, Publications Discovery and Antiviral Activity of the Novel 3CL Protease Inhibitor ALG-097558 in the SARS-CoV-2 Hamster Infection Model
ALG-055009, Publications Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist, for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia
ALG-000184, Publications Safety, Pharmacokinetics, and Antiviral Activity of the Class II Capsid Assembly Modulator ALG-000184 in Subjects with Chronic Hepatitis B
Other, Publications Incorporation of novel siRNA chemistries significantly improves the potency and durability of HBV siRNAs in the AAV-HBV mouse model
Other, Publications The HBV siRNA, ALG-125755, demonstrates a favorable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model
Preclinical, Publications Discovery of oral PD-L1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B
Publication, Publications Opportunities and Challenges in Targeting the Proofreading Activity of SARS-CoV-2 Polymerase Complex